Skip to Content
US Videos

Is There Opportunity in Teladoc?

The company that is eliminating waiting rooms at the doctor’s office.

Editor’s note: Read the latest on how the coronavirus is rattling the markets and what investors can do to navigate it.

Andrew Willis: Some of the most successful stocks in the pandemic have soared as services went online. Zoom, Shopify, and Amazon solved our communications and consumer needs--but what about our health?

Enter Teladoc (TDOC), a leading provider of virtual healthcare technology. The company provides online doctor consultations alongside a suite of software that offers ongoing care in fields like cardiology, diabetes, weight, and mental health management.

Amidst a massive medical crisis, it’s surprising to see Teladoc still trading around our fair value estimates--forgoing, so far, the same level of hype that we’ve seen inflate other pandemic-related stocks to unrealistic valuations.

One of the main reasons is our increased confidence in the staying power of growth achieved, beyond the pandemic. Equity analyst Soo Romanoff says the acquisition and integration of similar online health-service providers InTouch and Livongo went better than expected, offering diversification of services and new growth opportunities. And the company’s subscription-based revenue model is set to recur yearly at around 80%!

As of late last year, the company had more than 54 million members and 50,000 licensed providers, allowing it to match patients within 10 minutes of requesting care or a consultation. These kinds of game-changing figures have us raising our fair value estimate by around 23% to $225 U.S. dollars a share.

With an aging North American population, ongoing mobility restrictions, and opportunities to improve the acceptance of telemedicine insurance coverage with the new U.S. administration, we think this company’s in good shape.

For Morningstar, I’m Andrew Willis.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.